World's Best Scientists 2026 revealed!
Philippe Moreau

Philippe Moreau

D-Index & Metrics

Medicine

D-Index
152
Citations
97383
World Ranking
1067
National Ranking
25

Overview

Philippe Moreau is affiliated with the University of Nantes in France and has contributed significantly to research in hematology, oncology, and molecular biology with a primary focus on multiple myeloma and related therapies. Their work involves a broad examination of cancer treatments, protein degradation, peptidase inhibition, and immunotherapy methods such as CAR-T cell therapy.

Moreau's recent notable publications include:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma, 2023, New England Journal of Medicine

Frequent co-authors who have collaborated with Moreau include:

  • Xavier Leleu
  • Aurore Perrot
  • María-Victoria Mateos
  • Thierry Façon
  • Cyrille Touzeau

Moreau publishes extensively in recognized scientific venues, with major contributions appearing in:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Haematologica

The main fields of study for Moreau's work encompass:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, their subfield focus areas include:

  • Hematology
  • Molecular Biology
  • Oncology
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

Key topics covered by Moreau's research comprise:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • CAR-T Cell Therapy Research
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Lymphocytic Leukemia Research

Best Publications

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

    Morie A. Gertz;Ray Comenzo;Rodney H. Falk;Jean Paul Fermand

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

    Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Niccolo Bolli;Hervé Avet-Loiseau;David C. Wedge;Peter Van Loo

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

    Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen

Frequent Co-Authors

Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Michel Attal
Michel Attal Janssen (Belgium)
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Paul G. Richardson
Paul G. Richardson Harvard University
Xavier Leleu
Xavier Leleu Harvard University
Denis Caillot
Denis Caillot Grenoble Alpes University
Dominique Guyomard
Dominique Guyomard Centre national de la recherche scientifique, CNRS
Jean-Luc Harousseau
Jean-Luc Harousseau University of Nantes
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean pursuing the traditional MD. Many healthcare professionals choose alternative paths, such as nursing, which offer flexibility and various career growth opportunities. With the rise of remote learning, students can now access high-quality programs from anywhere, making it easier to advance their education while balancing work or family commitments.

For those interested in becoming an advanced practice nurse, check out the most affordable nurse practitioner programs available online. If you're just starting your nursing journey, there are also many online nursing programs designed to help you begin your career efficiently and affordably.

Registered nurses looking to further their credentials can explore the average cost of rn to bsn programs to find affordable options that fit their budget. For advanced professionals aiming for leadership or research roles, pursuing an online nursing doctorate can open doors to exciting new opportunities in academia, administration, and beyond.

Best Scientists Citing Philippe Moreau

Trending Scientists

Recently Published Articles